In lung cancer, reports indicate decreased HSPA5 expression with Aftanib by measuring the level of HSPA5 mRNA before and after treatment (Pancewicz-Wojtkiewicz and Bernatowicz, 2017). The gene discussed is HSPA5; the disease is lung carcinoma.